The second round of Medicare Part D price negotiations will feature two drugs familiar to rheumatologists — Ofev and Otezla — ...

Pfizer has received approval from the US FDA for its rheumatoid arthritis (RA) drug, Xeljanz, which is the first approved RA treatment in a new class of medicines known as Janus kinase inhibitors ...

Biologic disease-modifying antirheumatic drugs (DMARDs) such as adalimumab, etanercept and infliximab are effective at reducing symptoms and slowing progression of rheumatoid arthritis (RA).

autoantibodies against citrullinated IGF2BP1 are detected in patients with rheumatoid arthritis and positively correlate with disease severity.

Rheumatoid arthritis (RA) is a chronic inflammatory disorder that primarily affects the joints, leading to pain and disability. The introduction of biologic drugs has significantly improved ...